Abstract: A 4,4?-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(2-mercaptoquinolato)(PiPr3)2 moieties, its synthesis, and its use as a catalyst.
Abstract: Methods and compositions are provided for treating endometriosis in an individual, and the pain associated with endometriosis. Aspects of the methods include administering to the individual an agent that promotes ALDH activity.
Type:
Grant
Filed:
February 25, 2022
Date of Patent:
May 7, 2024
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Eric Gross, Daria Mochly-Rosen, Stacy Lynn McAllister
Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Type:
Grant
Filed:
March 21, 2022
Date of Patent:
April 23, 2024
Assignee:
FORMA Therapeutics, Inc.
Inventors:
Patrick F. Kelly, Susan Ashwell, Blythe Thomson, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Abstract: This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and/or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.
Type:
Grant
Filed:
October 31, 2022
Date of Patent:
April 16, 2024
Assignee:
Alkahest, Inc.
Inventors:
Meghan Kerrisk Campbell, Eva Czirr, Reema Harish
Abstract: The present disclosure provides for compounds of Formula (I), its corresponding compounds of Formula (II) or salts thereof and their use as fluorogenic pH sensors.
Abstract: The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.
Type:
Grant
Filed:
May 27, 2021
Date of Patent:
April 2, 2024
Assignee:
The Johns Hopkins University
Inventors:
Jun Liu, Sam Hong, Brett R. Ullman, Joseph E. Semple, Kana Yamamoto, Puneet Kumar, Magesh Sadagopan, Jennifer C. Schmitt
Abstract: Provided are enantiomers of MDMA, such as R-MDMA and S-MDMA, and non-racemic mixtures thereof. In some embodiments, the provided mixtures comprise R-MDMA in enantiomeric excess. In other aspects, provided are methods of making such enantiomers and non-racemic mixtures, compositions thereof, and methods of using the same. In some aspects, features of the provided mixtures, compositions, and methods include improved pharmacokinetics, reduced toxicity, such as neurotoxicity, and a reduced potential for abuse. In some embodiments, improved pharmacokinetics include a reduced duration of action. In some embodiments, reduced toxicity and abuse potential result from distinct binding profiles compared to racemic MDMA, R-MDMA, or S-MDMA.
Abstract: A 1-cyclopropyl-6-fluoro-4-oxo-7-(4-((2-thioxobenzo[d]oxazol-3(2H)-yl)methyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.
Type:
Grant
Filed:
September 13, 2023
Date of Patent:
March 12, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: The invention relates to a high-performance sky blue thermally activated delayed fluorescent material, manufacturing method thereof, and application thereof, which solves the problems of the prior art. Through clever molecular design, a series of sky-blue thermally activated delayed fluorescent materials with less singlet-triplet energy level difference, high luminous efficiency, and fast-rate reverse intersystem crossing constant were synthesized, while fine-tuning of the structure and spectrum thereof were realized.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
March 12, 2024
Assignee:
WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD.
Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
March 5, 2024
Assignee:
Novartis AG
Inventors:
Sung David C. Kim, Zaixing Li, Chui Lu, Danuta Lubicka, James Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
Abstract: This invention is related to the use of a volatile antimicrobial compound against pathogens. The volatile antimicrobial compounds provided include certain oxaborole compounds, for example benzoxaboroles. Delivery systems are provided to take advantage of the volatile nature of these antimicrobial compounds. The method and use disclosed can be combined with other volatile compounds.
Type:
Grant
Filed:
December 13, 2021
Date of Patent:
March 5, 2024
Assignee:
AGROFRESH INC.
Inventors:
Daniel MacLean, David H. Young, Richard M. Jacobson, Maurice C. Yap, Rodrigo A. Cifuentes, Donald H. DeVries, Joseph D. Eckelbarger
Abstract: The use of tocotrienols in medicine, veterinary or cosmetics, namely through the stabilization of tocotrienols, in particular in cosmetic formulations without hampering its functions in the skin is provided. In particular, the modification of tocotrienols with nicotinic acid results in the stabilization of the molecule and the penetration profile in human skin. The compounds and composition of are useful in medicine, veterinary or cosmetic industry namely in the prevention, therapy or treatment of skin diseases, skin disorders, or as a therapy or treatment of acne, seborrheic dermatitis or as an anti-aging agent.
Type:
Grant
Filed:
October 8, 2021
Date of Patent:
February 27, 2024
Assignee:
GLOBAL SCIENTIFIC
Inventors:
Daniel Kern, Kent Mirkhani, Ivo Manuel Ascensão Aroso, Ricardo De Sá Bessa, Rui Luis Goncalves Dos Reis
Abstract: A method for treating a cancer involving one or more translocations generating an oncogenic fusion transcription factor that requires p300/CBP for activity in an animal, comprising administering a compound of formula (I): or a pharmaceutically acceptable salt thereof to the animal.
Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
Abstract: Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.
Type:
Grant
Filed:
May 31, 2021
Date of Patent:
February 6, 2024
Assignees:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventors:
Or Kakhlon, Miguel Enrique Weil, Leonardo Javier Solmesky
Abstract: A composition for treatment of cellulitis is provided that includes by weight: about 85% transdermal cream; about 5% Cephalexin or Clindamycin; about 5% Ketoprofen; and about 5% Lidocaine. The composition has a density of about 1 gram per milliliter.
Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
Abstract: ?-Amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases, and cancer.
Type:
Grant
Filed:
January 31, 2022
Date of Patent:
January 2, 2024
Assignee:
Merck Patent GmbH
Inventors:
Markus Klein, Oliver Schadt, Christina Esdar